Dimerix

Dimerix R&D Expenses

The Research & Development Expenses of Dimerix (DXB.AX) as of Oct 11, 2026 is 36.03 M AUD. In the previous year, Research & Development Expenses was 27.32 M AUD — a change of 31.85% (higher).

R&D Expenses

36.03 MAUD

YoY

31.85%

Last updated:

Research & Development Expenses of Dimerix is 2026 36.03 M AUD. Research & Development Expenses of Dimerix was 2025 27.32 M AUD. It decreases by 31.85% higher compared to the previous year.

The Dimerix R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2019
2.84 M AUD
Jan 1, 2020
5.54 M AUD
Jan 1, 2021
9.33 M AUD
Jan 1, 2022
14.39 M AUD
Jan 1, 2023
20.47 M AUD
Jan 1, 2024
21.10 M AUD
Jan 1, 2025
27.32 M AUD
Jan 1, 2026
36.03 M AUD
The Dimerix R&D Expenses history
YEARR&D ExpensesYoY
36.03 MAUD+31.85%
27.32 MAUD+29.51%
21.10 MAUD+3.05%
20.47 MAUD+42.29%
14.39 MAUD+54.19%
9.33 MAUD+68.51%
5.54 MAUD+95.21%
2.84 MAUD+38.32%
2.05 MAUD+133.57%
878,118.00AUD+49.07%
589,075.00AUD+178.26%
211,698.00AUD-2.77%
217,721.00AUD—
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Research & Development Expenses of Dimerix is 36.03 M AUD in 2026.

Research & Development Expenses of Dimerix changed from 27.32 M AUD to 36.03 M AUD, representing a 31.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Dimerix since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Dimerix historically and in real time.

Access this data via the Eulerpool API

Income Statement — Dimerix

All Key Metrics — Dimerix